Barry J Maron1, Ethan J Rowin2, Susan A Casey2, John R Lesser2, Ross F Garberich2, Deepa M McGriff2, Martin S Maron2. 1. From Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, MN (B.J.M., S.A.C., J.R.L., R.F.G., D.M.M.); and Hypertrophic Cardiomyopathy Center, Tufts Medical Center, Boston MA (E.J.R., M.S.M.). hcm.maron@mhif.org. 2. From Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, MN (B.J.M., S.A.C., J.R.L., R.F.G., D.M.M.); and Hypertrophic Cardiomyopathy Center, Tufts Medical Center, Boston MA (E.J.R., M.S.M.).
Abstract
BACKGROUND: Youthful age has been considered the time of greatest risk for patients with hypertrophic cardiomyopathy (HCM), largely because of the possibility of sudden death. The last 2 decades have witnessed more reliable identification of at-risk patients and utilization of implantable cardioverter-defibrillators for prevention of sudden death, and other contemporary treatment options. Whether such management advances have significantly altered the considerable mortality rate for young HCM patients remains unresolved. METHODS AND RESULTS: We studied long-term outcome in 474 consecutive HCM patients between 7 and 29 years of age presenting at 2 referral institutions. Over 7.1±5.1 years of follow-up (6.0 [3.0, 10.0]), 452 patients (95%) survived, with 95% experiencing no or mild symptoms. HCM-related death occurred in 18 patients (3%; 0.54%/y): arrhythmic sudden death (n=12), progressive heart failure and heart transplant complications (n=5), or postoperatively (n=1). In contrast, aborted life-threatening events occurred in 63 other high-risk patients (13%) with implantable cardioverter-defibrillator interventions for ventricular tachyarrhythmias (n=31), resuscitated out-of-hospital cardiac arrest (n=20), or heart transplant for advanced heart failure (n=12), 1.8%/y, 3-fold higher than HCM mortality. Five- and 10-year survival (considering only HCM deaths) was high (97% and 94%, respectively), virtually identical to that reported in middle-aged adult HCM patients (98% and 94%, P=0.23). CONCLUSIONS: In a large hospital-based cohort of young HCM patients, representing an age group considered at greatest risk, low mortality rates can be achieved with the application of contemporary cardiovascular treatment strategies, largely because of reliable identification of high-risk patients who benefited from implantable cardioverter-defibrillators for sudden death prevention, thereby creating the opportunity for extended longevity and good quality of life.
BACKGROUND: Youthful age has been considered the time of greatest risk for patients with hypertrophic cardiomyopathy (HCM), largely because of the possibility of sudden death. The last 2 decades have witnessed more reliable identification of at-risk patients and utilization of implantable cardioverter-defibrillators for prevention of sudden death, and other contemporary treatment options. Whether such management advances have significantly altered the considerable mortality rate for young HCM patients remains unresolved. METHODS AND RESULTS: We studied long-term outcome in 474 consecutive HCM patients between 7 and 29 years of age presenting at 2 referral institutions. Over 7.1±5.1 years of follow-up (6.0 [3.0, 10.0]), 452 patients (95%) survived, with 95% experiencing no or mild symptoms. HCM-related death occurred in 18 patients (3%; 0.54%/y): arrhythmic sudden death (n=12), progressive heart failure and heart transplant complications (n=5), or postoperatively (n=1). In contrast, aborted life-threatening events occurred in 63 other high-risk patients (13%) with implantable cardioverter-defibrillator interventions for ventricular tachyarrhythmias (n=31), resuscitated out-of-hospital cardiac arrest (n=20), or heart transplant for advanced heart failure (n=12), 1.8%/y, 3-fold higher than HCM mortality. Five- and 10-year survival (considering only HCM deaths) was high (97% and 94%, respectively), virtually identical to that reported in middle-aged adult HCM patients (98% and 94%, P=0.23). CONCLUSIONS: In a large hospital-based cohort of young HCM patients, representing an age group considered at greatest risk, low mortality rates can be achieved with the application of contemporary cardiovascular treatment strategies, largely because of reliable identification of high-risk patients who benefited from implantable cardioverter-defibrillators for sudden death prevention, thereby creating the opportunity for extended longevity and good quality of life.
Authors: Lisa L Shah; Sandra Daack-Hirsch; Anne L Ersig; Anthony Paik; Ferhaan Ahmad; Janet Williams Journal: West J Nurs Res Date: 2018-12-12 Impact factor: 1.967
Authors: Carolyn Y Ho; Sharlene M Day; Euan A Ashley; Michelle Michels; Alexandre C Pereira; Daniel Jacoby; Neal K Lakdawala; James S Ware; Adam S Helms; Steven D Colan; Christine E Seidman; Iacopo Olivotto Journal: Circulation Date: 2019-03-19 Impact factor: 29.690
Authors: Julian R Homburger; Eric M Green; Colleen Caleshu; Margaret S Sunitha; Rebecca E Taylor; Kathleen M Ruppel; Raghu Prasad Rao Metpally; Steven D Colan; Michelle Michels; Sharlene M Day; Iacopo Olivotto; Carlos D Bustamante; Frederick E Dewey; Carolyn Y Ho; James A Spudich; Euan A Ashley Journal: Proc Natl Acad Sci U S A Date: 2016-05-31 Impact factor: 11.205
Authors: Martin S Maron; Ethan J Rowin; Benjamin S Wessler; Paula J Mooney; Amber Fatima; Parth Patel; Benjamin C Koethe; Mikhail Romashko; Mark S Link; Barry J Maron Journal: JAMA Cardiol Date: 2019-07-01 Impact factor: 14.676
Authors: Silvio Henrique Barberato; Minna Moreira Dias Romano; Adenalva Lima de Souza Beck; Ana Clara Tude Rodrigues; André Luiz Cerqueira de Almeida; Bruna Morhy Borges Leal Assunção; Eliza de Almeida Gripp; Fabio Villaça Guimarães Filho; Henry Abensur; José Maria Del Castillo; Marcelo Haertel Miglioranza; Marcelo Luiz Campos Vieira; Márcio Vinicius Lins de Barros; Maria do Carmo Pereira Nunes; Maria Estefania Bosco Otto; Renato de Aguiar Hortegal; Rodrigo Bellio de Mattos Barretto; Thais Harada Campos; Vicente Nicoliello de Siqueira; Samira Saady Morhy Journal: Arq Bras Cardiol Date: 2019-08-08 Impact factor: 2.000